Potential Drugs in COVID-19 Management

Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020, 395(10229), 1054-1062.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]

Wu, Z.; McGoogan, J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13), 1239-1242.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]

Mahase, E. Long covid could be four different syndromes, review suggests. BMJ, 2020, 371, m3981.
[http://dx.doi.org/10.1136/bmj.m3981] [PMID: 33055076]

Liu, J.; Liu, Y.; Xiang, P.; Pu, L.; Xiong, H.; Li, C.; Zhang, M.; Tan, J.; Xu, Y.; Song, R. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. J. Transl. Med., 2020, 18(1), 206.
[http://dx.doi.org/10.1186/s12967-020-02374-0] [PMID: 32434518]

Cao, Q.; Chen, Y.C.; Chen, C.L.; Chiu, C.H. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J. Formos. Med. Assoc., 2020, 119(3), 670-673.
[http://dx.doi.org/10.1016/j.jfma.2020.02.009] [PMID: 32139299]

Peiris, J.S.M.; Chu, C.M.; Cheng, V.C.C.; Chan, K.S.; Hung, I.F.N.; Poon, L.L.M.; Law, K.I.; Tang, B.S.F.; Hon, T.Y.W.; Chan, C.S.; Chan, K.H.; Ng, J.S.C.; Zheng, B.J.; Ng, W.L.; Lai, R.W.M.; Guan, Y.; Yuen, K.Y. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet, 2003, 361(9371), 1767-1772.
[http://dx.doi.org/10.1016/S0140-6736(03)13412-5] [PMID: 12781535]

Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223), 507-513.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]

Huang, W.H.; Teng, L.C.; Yeh, T.K.; Chen, Y.J.; Lo, W.J.; Wu, M.J.; Chin, C.S.; Tsan, Y.T.; Lin, T.C.; Chai, J.W.; Lin, C.F.; Tseng, C.H.; Liu, C.W.; Wu, C.M.; Chen, P.Y.; Shi, Z.Y.; Liu, P.Y. 2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. J. Microbiol. Immunol. Infect., 2020, 53(3), 481-484.
[http://dx.doi.org/10.1016/j.jmii.2020.02.009] [PMID: 32111449]

Lee, P.I.; Hu, Y.L.; Chen, P.Y.; Huang, Y.C.; Hsueh, P.R. Are children less susceptible to COVID-19? J. Microbiol. Immunol. Infect., 2020, 53(3), 371-372.
[http://dx.doi.org/10.1016/j.jmii.2020.02.011] [PMID: 32147409]

Zamorano Cuervo, N.; Grandvaux, N. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. eLife, 2020, 9, e61390.
[http://dx.doi.org/10.7554/eLife.61390] [PMID: 33164751]

Ni, W.; Yang, X.; Yang, D.; Bao, J.; Li, R.; Xiao, Y.; Hou, C.; Wang, H.; Liu, J.; Yang, D.; Xu, Y.; Cao, Z.; Gao, Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care, 2020, 24(1), 422.
[http://dx.doi.org/10.1186/s13054-020-03120-0] [PMID: 32660650]

Hofmann, H.; Pyrc, K.; van der Hoek, L.; Geier, M.; Berkhout, B.; Pöhlmann, S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci., 2005, 102(22), 7988-7993.
[http://dx.doi.org/10.1073/pnas.0409465102] [PMID: 15897467]

Lee, K.H.; Yoo, S.G.; Cho, Y.; Kwon, D.E.; La, Y.; Han, S.H.; Kim, M.S.; Choi, J.S.; Kim, S.I.; Kim, Y.S.; Min, Y.H.; Cheong, J.W.; Kim, J.S.; Song, Y.G. Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients. J. Microbiol. Immunol. Infect., 2021, 54(2), 253-260.
[http://dx.doi.org/10.1016/j.jmii.2019.05.007] [PMID: 31262511]

Lee, P.I.; Hsueh, P.R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J. Microbiol. Immunol. Infect., 2020, 53(3), 365-367.
[http://dx.doi.org/10.1016/j.jmii.2020.02.001] [PMID: 32035811]

To, K.K.W.; Tsang, O.T.Y.; Leung, W.S.; Tam, A.R.; Wu, T.C.; Lung, D.C.; Yip, C.C.Y.; Cai, J.P.; Chan, J.M.C.; Chik, T.S.H.; Lau, D.P.L.; Choi, C.Y.C.; Chen, L.L.; Chan, W.M.; Chan, K.H.; Ip, J.D.; Ng, A.C.K.; Poon, R.W.S.; Luo, C.T.; Cheng, V.C.C.; Chan, J.F.W.; Hung, I.F.N.; Chen, Z.; Chen, H.; Yuen, K.Y. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect. Dis., 2020, 20(5), 565-574.
[http://dx.doi.org/10.1016/S1473-3099(20)30196-1] [PMID: 32213337]

Peeri, N.C.; Shrestha, N.; Rahman, M.S.; Zaki, R.; Tan, Z.; Bibi, S.; Baghbanzadeh, M.; Aghamohammadi, N.; Zhang, W.; Haque, U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned? Int. J. Epidemiol., 2020, 49(3), 717-726.
[http://dx.doi.org/10.1093/ije/dyaa033] [PMID: 32086938]

Semenova, Y.; Trenina, V.; Pivina, L.; Glushkova, N.; Zhunussov, Y.; Ospanov, E.; Bjørklund, G. The lessons of COVID-19, SARS, and MERS: Implications for preventive strategies. Int. J. Healthc. Manag., 2022, 15(4), 314-324.
[http://dx.doi.org/10.1080/20479700.2022.2051126]

Lui, G.; Guaraldi, G. Drug treatment of COVID-19 infection. Curr. Opin. Pulm. Med., 2023, 29(3), 174-183.
[http://dx.doi.org/10.1097/MCP.0000000000000953] [PMID: 36917228]

Yuan, Y.; Jiao, B.; Qu, L.; Yang, D.; Liu, R. The development of COVID-19 treatment. Front. Immunol., 2023, 14, 1125246.
[http://dx.doi.org/10.3389/fimmu.2023.1125246] [PMID: 36776881]

Chu, C.M.; Cheng, V.C.; Hung, I.F.; Wong, M.M.; Chan, K.H.; Chan, K.S.; Kao, R.Y.; Poon, L.L.; Wong, C.L.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax, 2004, 59(3), 252-256.
[http://dx.doi.org/10.1136/thorax.2003.012658] [PMID: 14985565]

Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med., 2020, 382(19), 1787-1799.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]

Lim, J.; Jeon, S.; Shin, H-Y.; Kim, M.J.; Seong, Y.M.; Lee, W.J.; Choe, K-W.; Kang, Y.M.; Lee, B.; Park, S-J. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci., 2020, 35(6), e79.
[http://dx.doi.org/10.3346/jkms.2020.35.e79] [PMID: 32056407]

Kim, U.J.; Won, E.J.; Kee, S.J.; Jung, S.I.; Jang, H.C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir. Ther., 2016, 21(5), 455-459.
[http://dx.doi.org/10.3851/IMP3002] [PMID: 26492219]

Rosa, S.G.V.; Santos, W.C. Clinical trials on drug repositioning for COVID-19 treatment. Rev. Panam. Salud Publica, 2020, 44, 1.
[http://dx.doi.org/10.26633/RPSP.2020.40] [PMID: 32256547]

Dong, L.; Hu, S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther., 2020, 14(1), 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]

Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.; Shen, C.; Li, X.; Peng, L.; Huang, D.; Zhang, J.; Zhang, S.; Wang, F.; Liu, J.; Chen, L.; Chen, S.; Wang, Z.; Zhang, Z.; Cao, R.; Zhong, W.; Liu, Y.; Liu, L. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering, 2020, 6(10), 1192-1198.
[http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID: 32346491]

Cyranoski, D.; Abbott, A. Virus detectives seek source of SARS in China’s wild animals. Nature, 2003, 423(6939), 467.
[http://dx.doi.org/10.1038/423467a] [PMID: 12774078]

Morgenstern, B.; Michaelis, M.; Baer, P.C.; Doerr, H.W.; Cinatl, J., Jr Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun., 2005, 326(4), 905-908.
[http://dx.doi.org/10.1016/j.bbrc.2004.11.128] [PMID: 15607755]

Khalili, J.S.; Zhu, H.; Mak, N.S.A.; Yan, Y.; Zhu, Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J. Med. Virol., 2020, 92(7), 740-746.
[http://dx.doi.org/10.1002/jmv.25798] [PMID: 32227493]

Elfiky, A.A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci., 2020, 253, 117592.
[http://dx.doi.org/10.1016/j.lfs.2020.117592] [PMID: 32222463]

Holshue, M.L.; DeBolt, C.; Lindquist, S.; Lofy, K.H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A.; Diaz, G.; Cohn, A.; Fox, L.; Patel, A.; Gerber, S.I.; Kim, L.; Tong, S.; Lu, X.; Lindstrom, S.; Pallansch, M.A.; Weldon, W.C.; Biggs, H.M.; Uyeki, T.M.; Pillai, S.K. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med., 2020, 382(10), 929-936.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]

Agostini, M.L.; Andres, E.L.; Sims, A.C.; Graham, R.L.; Sheahan, T.P.; Lu, X.; Smith, E.C.; Case, J.B.; Feng, J.Y.; Jordan, R.; Ray, A.S.; Cihlar, T.; Siegel, D.; Mackman, R.L.; Clarke, M.O.; Baric, R.S.; Denison, M.R. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio, 2018, 9(2), e00221-18.
[http://dx.doi.org/10.1128/mBio.00221-18] [PMID: 29511076]

Lim, S.Y.; Guo, Z.; Liu, P.; McKay, L.G.A.; Storm, N.; Griffiths, A.; Qu, M.D.; Finberg, R.W.; Somasundaran, M.; Wang, J.P. Anti-SARS-CoV-2 activity of adamantanes in vitro and in animal models of infection. COVID, 2022, 2(11), 1551-1563.
[http://dx.doi.org/10.3390/covid2110111] [PMID: 37274537]

deVries, T.; Dentiste, A.; Handiwala, L.; Jacobs, D. Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol. Ther., 2019, 8(2), 449-460.
[http://dx.doi.org/10.1007/s40120-019-0144-1] [PMID: 31372936]

Zhou, Y.; Gammeltoft, K.A.; Galli, A.; Offersgaard, A.; Fahnøe, U.; Ramirez, S.; Bukh, J.; Gottwein, J.M. Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in vitro. Viruses, 2021, 13(10), 2082.
[http://dx.doi.org/10.3390/v13102082] [PMID: 34696509]

Rejdak, K.; Fiedor, P.; Bonek, R.; Goch, A.; Gala-Błądzińska, A.; Chełstowski, W.; Łukasiak, J.; Kiciak, S.; Dąbrowski, P.; Dec, M.; Król, Z.J.; Papuć, E.; Zasybska, A.; Segiet, A.; Grieb, P. The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. Contemp. Clin. Trials, 2022, 116, 106755.
[http://dx.doi.org/10.1016/j.cct.2022.106755] [PMID: 35390511]

Barczyk, A.; Czajkowska-Malinowska, M.; Farnik, M.; Barczyk, M.; Boda, Ł.; Cofta, S.; Duława, J.; Dyrbuś, M.; Harat, R.; Huk, M.; Kotecka, S.; Nahorecki, A.; Nasiłowski, J.; Naumnik, W.; Przybylski, G.; Słaboń-Willand, M.; Skoczyński, S.; Wita, K.; Zioło, G.; Kuna, P. Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study. Respir. Med., 2023, 212, 107198.
[http://dx.doi.org/10.1016/j.rmed.2023.107198] [PMID: 36931576]

Keyser, L.A.; Karl, M.; Nafziger, A.N.; Bertino, J.S., Jr Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med., 2000, 160(10), 1485-1488.
[http://dx.doi.org/10.1001/archinte.160.10.1485] [PMID: 10826462]

Hayden, F.G.; Hoffman, H.E.; Spyker, D.A. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob. Agents Chemother., 1983, 23(3), 458-464.
[http://dx.doi.org/10.1128/AAC.23.3.458] [PMID: 6847173]

Touret, F.; de Lamballerie, X. Of chloroquine and COVID-19. Antiviral Res., 2020, 177, 104762.
[http://dx.doi.org/10.1016/j.antiviral.2020.104762] [PMID: 32147496]

Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]

Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, 2(1), 69.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]

Boulware, D.R.; Pullen, M.F.; Bangdiwala, A.S.; Pastick, K.A.; Lofgren, S.M.; Okafor, E.C.; Skipper, C.P.; Nascene, A.A.; Nicol, M.R.; Abassi, M.; Engen, N.W.; Cheng, M.P.; LaBar, D.; Lother, S.A.; MacKenzie, L.J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L.E.; Schwartz, I.S.; McDonald, E.G.; Rajasingham, R.; Lee, T.C.; Hullsiek, K.H. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med., 2020, 383(6), 517-525.
[http://dx.doi.org/10.1056/NEJMoa2016638] [PMID: 32492293]

Bhimraj, A.; Morgan, R.L.; Shumaker, A.H.; Baden, L.; Cheng, V.C.C.; Edwards, K.M.; Gallagher, J.C.; Gandhi, R.T.; Muller, W.J.; Nakamura, M.M.; O’Horo, J.C.; Shafer, R.W.; Shoham, S.; Murad, M.H.; Mustafa, R.A.; Sultan, S.; Falck-Ytter, Y. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis., 2022, ciac724.
[http://dx.doi.org/10.1093/cid/ciac724] [PMID: 36063397]

Luo, P.; Liu, Y.; Qiu, L.; Liu, X.; Liu, D.; Li, J. Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol., 2020, 92(7), 814-818.
[http://dx.doi.org/10.1002/jmv.25801] [PMID: 32253759]

Stone, J.H.; Frigault, M.J.; Serling-Boyd, N.J.; Fernandes, A.D.; Harvey, L.; Foulkes, A.S.; Horick, N.K.; Healy, B.C.; Shah, R.; Bensaci, A.M.; Woolley, A.E.; Nikiforow, S.; Lin, N.; Sagar, M.; Schrager, H.; Huckins, D.S.; Axelrod, M.; Pincus, M.D.; Fleisher, J.; Sacks, C.A.; Dougan, M.; North, C.M.; Halvorsen, Y.D.; Thurber, T.K.; Dagher, Z.; Scherer, A.; Wallwork, R.S.; Kim, A.Y.; Schoenfeld, S.; Sen, P.; Neilan, T.G.; Perugino, C.A.; Unizony, S.H.; Collier, D.S.; Matza, M.A.; Yinh, J.M.; Bowman, K.A.; Meyerowitz, E.; Zafar, A.; Drobni, Z.D.; Bolster, M.B.; Kohler, M.; D’Silva, K.M.; Dau, J.; Lockwood, M.M.; Cubbison, C.; Weber, B.N.; Mansour, M.K. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med., 2020, 383(24), 2333-2344.
[http://dx.doi.org/10.1056/NEJMoa2028836] [PMID: 33085857]

Salvarani, C.; Dolci, G.; Massari, M.; Merlo, D.F.; Cavuto, S.; Savoldi, L.; Bruzzi, P.; Boni, F.; Braglia, L.; Turrà, C.; Ballerini, P.F.; Sciascia, R.; Zammarchi, L.; Para, O.; Scotton, P.G.; Inojosa, W.O.; Ravagnani, V.; Salerno, N.D.; Sainaghi, P.P.; Brignone, A.; Codeluppi, M.; Teopompi, E.; Milesi, M.; Bertomoro, P.; Claudio, N.; Salio, M.; Falcone, M.; Cenderello, G.; Donghi, L.; Del Bono, V.; Colombelli, P.L.; Angheben, A.; Passaro, A.; Secondo, G.; Pascale, R.; Piazza, I.; Facciolongo, N.; Costantini, M. Effect of tocilizumab vs. standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern. Med., 2021, 181(1), 24-31.
[http://dx.doi.org/10.1001/jamainternmed.2020.6615] [PMID: 33080005]

Hermine, O.; Mariette, X.; Tharaux, P.L.; Resche-Rigon, M.; Porcher, R.; Ravaud, P.; Bureau, S.; Dougados, M.; Tibi, A.; Azoulay, E.; Cadranel, J.; Emmerich, J.; Fartoukh, M.; Guidet, B.; Humbert, M.; Lacombe, K.; Mahevas, M.; Pene, F.; Pourchet-Martinez, V.; Schlemmer, F.; Yazdanpanah, Y.; Baron, G.; Perrodeau, E.; Vanhoye, D.; Kedzia, C.; Demerville, L.; Gysembergh-Houal, A.; Bourgoin, A.; Dalibey, S.; Resche-Rigon, M.; Raked, N.; Mameri, L.; Alary, S.; Hamiria, S.; Bariz, T.; Semri, H.; Hai, D.M.; Benafla, M.; Belloul, M.; Vauboin, P.; Flamand, S.; Pacheco, C.; Walter-Petrich, A.; Stan, E.; Benarab, S.; Nyanou, C.; Montlahuc, C.; Biard, L.; Charreteur, R.; Dupré, C.; Cardet, K.; Lehmann, B.; Baghli, K.; Madeleine, C.; D’Ortenzio, E.; Puéchal, O.; Semaille, C.; Savale, L.; Harrois, A.; Figueiredo, S.; Duranteau, J.; Anguel, N.; Monnet, X.; Richard, C.; Teboul, J-L.; Durand, P.; Tissieres, P.; Jevnikar, M.; Montani, D.; Pavy, S.; Noel, N.; Lambotte, O.; Escaut, L.; Jauréguiberry, S.; Baudry, E.; Verny, C.; Lefèvre, E.; Zaidan, M.; Le Tiec, C.L.T.; Verstuyft, C.V.; Roques, A-M.; Grimaldi, L.; Molinari, D.; Leprun, G.; Fourreau, A.; Cylly, L.; Virlouvet, M.; Meftali, R.; Fabre, S.; Licois, M.; Mamoune, A.; Boudali, Y.; Georgin-Lavialle, S.; Senet, P.; Soria, A.; Parrot, A.; François, H.; Rozensztajn, N.; Blin, E.; Choinier, P.; Camuset, J.; Rech, J-S.; Canellas, A.; Rolland-Debord, C.; Lemarié, N.; Belaube, N.; Nadal, M.; Siguier, M.; Petit-Hoang, C.; Chas, J.; Drouet, E.; Lemoine, M.; Phibel, A.; Aunay, L.; Bertrand, E.; Ravato, S.; Vayssettes, M.; Adda, A.; Wilpotte, C.; Thibaut, P.; Fillon, J.; Debrix, I.; Fellahi, S.; Bastard, J-P.; Lefèvre, G.; Fallet, V.; Gottenberg, J-E.; Hansmann, Y.; Andres, E.; Bayer, S.; Becker, G.; Blanc, F.; Brin, S.; Castelain, V.; Chatelus, E.; Chatron, E.; Collange, O.; Danion, F.; De Blay, F.; Demonsant, E.; Diemunsch, P.; Diemunsch, S.; Felten, R.; Goichot, B.; Greigert, V.; Guffroy, A.; Heger, B.; Hutt, A.; Kaeuffer, C.; Kassegne, L.; Korganow, A.S.; Le Borgne, P.; Lefebvre, N.; Martin, T.; Mertes, P.M.; Metzger, C.; Meyer, N.; Nisand, G.; Noll, E.; Oberlin, M.; Ohlmann-Caillard, S.; Poindron, V.; Pottecher, J.; Ruch, Y.; Sublon, C.; Tayebi, H.; Weill, F.; Mekinian, A.; Chopin, D.; Fain, O.; Garnier, M.; Krause Le Garrec, J.; Morgand, M.; Pacanowski, J.; Urbina, T.; Mcavoy, C.; Pereira, M.; Aratus, G.; Berard, L.; Simon, T.; Daguenel Nguyen, A.; Antignac, M.; Leplay, C.; Arlet, J-B.; Diehl, J-L.; Bellenfant, F.; Blanchard, A.; Buffet, A.; Cholley, B.; Fayol, A.; Flamarion, E.; Godier, A.; Gorget, T.; Hamada, S-R.; Hauw-Berlemont, C.; Hulot, J-S.; Lebeaux, D.; Livrozet, M.; Michon, A.; Neuschwander, A.; Penet, M-A.; Planquette, B.; Ranque, B.; Sanchez, O.; Volle, G.; Briois, S.; Cornic, M.; Elisee, V.; Jesuthasan, D.; Djadi-Prat, J.; Jouany, P.; Junquera, R.; Henriques, M.; Kebir, A.; Lehir, I.; Meunier, J.; Patin, F.; Paquet, V.; TréHan, A.; Vigna, V.; Sabatier, B.; Bergerot, D.; Jouve, C.; Knosp, C.; Lenoir, O.; Mahtal, N.; Resmini, L.; Lescure, X.; Ghosn, J.; Bachelard, A.; Bironne, T.; Borie, R.; Bounhiol, A.; Boussard, C.; Chauffier, J.; Chalal, S.; Chalal, L.; Chansombat, M.; Crespin, P.; Crestani, B.; Daconceicao, O.; Deconinck, L.; Dieude; Dossier, A.; Dubert, M.; Ducrocq, G.; Fuentes, A.; Gervais, A.; Gilbert, M.; Isernia, V.; Ismael, S.; Joly, V.; Julia, Z.; Lariven, S.; Le Gac, S.; Le Pluart, D.; Louni, F.; Ndiaye, A.; Papo, T.; Parisey, M.; Phung, B.; Pourbaix, A.; Rachline, A.; Rioux, C.; Sautereau, A.; Steg, G.; Tharini, H.; Valayer, S.; Vallois, D.; Vermes, P.; Volpe, T.; Nguyen, Y.; Honsel, V.; Weiss, E.; Codorniu, A.; Zarrouk, V.; De Lastours, V.; Uzzan, M.; Gamany, N.; Rahli, R.; Louis, Z.; Boutboul, D.; Galicier, L.; Amara, Y.; Archer, G.; Benattia, A.; Bergeron, A.; Bondeelle, L.; De Castro, N.; Clément, M.; Darmont, M.; Denis, B.; Dupin, C.; Feredj, E.; Feyeux, D.; Joseph, A.; Lengliné, E.; Le Guen, P.; Liégeon, G.; Lorillon, G.; Mabrouki, A.; Mariotte, E.; Martin De Frémont, G.; Mirouse, A.; Molina, J-M.; Peffault De Latour, R.; Oksenhendler, E.; Saussereau, J.; Tazi, A.; Tudesq, J-J.; Zafrani, L.; Brindele, I.; Bugnet, E.; Celli Lebras, K.; Chabert, J.; Djaghout, L.; Fauvaux, C.; Jegu, A.L.; Kozaliewicz, E.; Meunier, M.; Tremorin, M-T.; Davoine, C.; Madeleine, I.; Caillat-Zucman, S.; Delaugerre, C.; Morin, F.; Sene, D.; Burlacu, R.; Chousterman, B.; Megarbane, B.; Richette, P.; Riveline, J-P.; Frazier, A.; Vicaut, E.; Berton, L.; Hadjam, T.; Vasquez-Ibarra, M.A.; Jourdaine, C.; Jacob, A.; Smati, J.; Renaud, S.; Manivet, P.; Pernin, C.; Suarez, L.; Semerano, L.; Abad, S.; Benainous, R.; Bloch Queyrat, C.; Bonnet, N.; Brahmi, S.; Cailhol; Cohen, Y.; Comparon, C.; Cordel, H.; Dhote, R.; Dournon, N.; Duchemann, B.; Ebstein, N.; Giroux-Leprieur, B.; Goupil De Bouille, J.; Jacolot, A.; Nunes, H.; Oziel, J.; Rathouin, V.; Rigal, M.; Roulot, D.; Tantet, C.; Uzunhan, Y.; Costedoat-Chalumeau, N.; Ait Hamou, Z.; Benghanem, S.; Blanche, P.; Canoui, E.; Carlier, N.; Chaigne, B.; Contejean, A.; Dunogue, B.; Dupland, P.; Durel - Maurisse, A.; Gauzit, R.; Jaubert, P.; Joumaa, H.; Jozwiak, M.; Kerneis, S.; Lachatre, M.; Lafoeste, H.; Legendre, P.; Luong Nguyen, L.B.; Marey, J.; Morbieu, C.; Mouthon, L.; Nguyen, L.; Palmieri, L-J.; Regent, A.; Szwebel, T-A.; Terrier, B.; Guerin, C.; Zerbit, J.; Cheref, K.; Chitour, K.; Cisse, M.S.; Clarke, A.; Clavere, G.; Dusanter, I.; Gaudefroy, C.; Jallouli, M.; Kolta, S.; Le Bourlout, C.; Marin, N.; Menage, N.; Moores, A.; Peigney, I.; Pierron, C.; Saleh-Mghir, S.; Vallet, M.; Michel, M.; Melica, G.; Lelievre, J-D.; Fois, E.; Lim, P.; Matignon, M.; Guillaud, C.; Thiemele, A.; Schmitz, D.; Bouhris, M.; Belazouz, S.; Languille, L.; Mekontso-Dessaps, A.; Sadaoui, T.; Mayaux, J.; Cacoub, P.; Corvol, J-C.; Louapre, C.; Sambin, S.; Mariani, L-L.; Karachi, C.; Tubach, F.; Estellat, C.; Gimeno, L.; Martin, K.; Bah, A.; Keo, V.; Ouamri, S.; Messaoudi, Y.; Yelles, N.; Faye, P.; Cavelot, S.; Larcheveque, C.; Annonay, L.; Benhida, J.; Zahrate-Ghoul, A.; Hammal, S.; Belilita, R.; Lecronier, M.; Beurton, A.; Haudebourg, L.; Deleris, R.; Le Marec, J.; Virolle, S.; Nemlaghi, S.; Bureau, C.; Mora, P.; De Sarcus, M.; Clovet, O.; Duceau, B.; Grisot, P.H.; Pari, M.; Arzoine, J.; Clarac, U.; Faure, M.; Delemazure, J.; Decavele, M.; Morawiec, E.; Demoule, A.; Dres, M.; Vautier, M.; Allenbach, Y.; Benveniste, O.; Leroux, G.; Rigolet, A.; Guillaume-Jugnot, P.; Domont, F.; Desbois, A.C.; Comarmond, C.; Champtiaux, N.; Toquet, S.; Ghembaza, A.; Vieira, M.; Maalouf, G.; Boleto, G.; Ferfar, Y.; Charbonnier, F.; Aguilar, C.; Alby-Laurent, F.; Alyanakian, M-A.; Bakouboula, P.; Broissand, C.; Burger, C.; Campos-Vega, C.; Chavarot, N.; Choupeaux, L.; Elie, C.; Fournier, B.; Granville, S.; Issorat, E.; Rouzaud, C.; Vimpere, D.; Geri, G.; Derridj, N.; Sguiouar, N.; Meddah, H.; Djadel, M.; Chambrin-Lauvray, H.; Duclos-Vallée, J-C.; Saliba, F.; Sacleux, S-C.; Koumis, I.; Michot, J-M.; Stoclin, A.; Colomba, E.; Pommeret, F.; Willekens, C.; Da Silva, R.; Dejean, V.; Mekid, Y.; Ben-Mabrouk, I.; Pradon, C.; Drouard, L.; Camara-Clayette, V.; Morel, A.; Garcia, G.; Mohebbi, A.; Berbour, F.; Dehais, M.; Pouliquen, A-L.; Klasen, A.; Soyez-Herkert, L.; London, J.; Keroumi, Y.; Guillot, E.; Grailles, G.; El Amine, Y.; Defrancq, F.; Fodil, H.; Bouras, C.; Dautel, D.; Gambier, N.; Dieye, T.; Bienvenu, B.; Lancon, V.; Lecomte, L.; Beziriganyan, K.; Asselate, B.; Allanic, L.; Kiouris, E.; Legros, M-H.; Lemagner, C.; Martel, P.; Provitolo, V.; Ackermann, F.; Le Marchand, M.; Clan Hew Wai, A.; Fremont, D.; Coupez, E.; Adda, M.; Duée, F.; Bernard, L.; Gros, A.; Henry, E.; Courtin, C.; Pattyn, A.; Guinot, P-G.; Bardou, M.; Maurer, A.; Jambon, J.; Cransac, A.; Pernot, C.; Mourvillier, B.; Servettaz, A.; Deslée, G.; Wynckel, A.; Benoit, P.; Marquis, E.; Roux, D.; Gernez, C.; Yelnik, C.; Poissy, J.; Nizard, M.; Denies, F.; Gros, H.; Mourad, J-J.; Sacco, E.; Renet, S. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern. Med., 2021, 181(1), 32-40.
[http://dx.doi.org/10.1001/jamainternmed.2020.6820] [PMID: 33080017]

Gordon, A.C.; Angus, D.C.; Derde, L.P.G. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med., 2021, 385(12), 1147-1149.
[http://dx.doi.org/10.1056/NEJMc2108482] [PMID: 34407335]

Jeronimo, C.M.P.; Farias, M.E.L.; Val, F.F.A.; Sampaio, V.S.; Alexandre, M.A.A.; Melo, G.C.; Safe, I.P.; Borba, M.G.S.; Netto, R.L.A.; Maciel, A.B.S.; Neto, J.R.S.; Oliveira, L.B.; Figueiredo, E.F.G.; Oliveira Dinelly, K.M.; de Almeida Rodrigues, M.G.; Brito, M.; Mourão, M.P.G.; Pivoto João, G.A.; Hajjar, L.A.; Bassat, Q.; Romero, G.A.S.; Naveca, F.G.; Vasconcelos, H.L.; de Araújo Tavares, M.; Brito-Sousa, J.D.; Costa, F.T.M.; Nogueira, M.L.; Baía-da-Silva, D.C.; Xavier, M.S.; Monteiro, W.M.; Lacerda, M.V.G.; de Lemos Vasconcelos, A.; Praia Marins, A.F.; de Oliveira Trindade, A.; Mendes Záu, A.S.; de Oliveira, A.C.; Azevedo Furtado, A.C.; Coelho Rocha, A.P.; da Silva Souza, A.; de Souza Dias, A.; Belém, A.; dos Santos, A.G.R.; da Silva Sousa, A.M.; da Silva, B.F.; Franco, B.L.; da Silva, B.M.; da Costa, B.L.G.; Sato Barros do Amaral, C.M.S.; Judice, C.C.; de Morais, C.E.P.; Camilo, C.C.; Sena da Silva, D.S.; Gomes Duarte, D.C.; da Silva, E.G.N.; da Silva Lemos, E.; de Fátima Ponte Frota, E.; do Nascimento, E.F.; de Almeida, E.S.; Marques, E.A.; de Almeida, E.M.M.; da Silva, E.L.; dos Santos, E.G.; da Silva Oliveira, E.; Martins Shimizu, F.M.; de Souza, F.R.F.; da Silva do Vale, F.; dos Santos de Almeida Lima, F.; da Fonseca, F.H.J.; Fontenelle, F.A.; de Azevedo Furtado, F.; Da Silva Pereira, G.; Bezerra, G.A.; Maciel Salazar, G.K.; da Silva Pereira, H.; de Melo, H.F.; Oliveira, I.N.; Pereira Filho, I.V.; Gomes, J.V.; e Silva Rosa, J.; Lemos, J.M.; Brutus, J.N.; Pessoa, K.P.; Costa Rodrigues, L.D.; Barros Cirino, L.E.; Mourão Filho, L.F.; Moura, L.; Barbosa, L.R.P.; de Souza, L.P.; Oliveira, L.B.; de Lima Ferreira, L.C.; dos Santos, M.M.; da Silva, M.V.R.; Rodrigues, M.P.; de Menezes, M.T.; dos Santos Mota, M.M.; Freire, M.; Corrêa, N.F.; Rocha, N.M.; Bittencourt, N.; de Melo Silva, N.G.; de Oliveira Saraiva, P.; de Sousa Monteiro, Q.; dos Santos, R.T.; Freire, R.S.; de Araújo Pinto, R.A.; Ferreira, R.B.; de Lima, R.S.; de Melo, R.F.T.; Saenz, S.T.; Alvarez Fernandes, S.S.; Vítor-Silva, S.; de Oliveira, T.M.R.; Tavella, T.A.; Câmara, T.T.; Santos, T.C.; Pinto, T.S.; dos Santos, T.W.R.; do Nascimento, V.A.; Sousa, B.W.P.; de Melo, W.F.; Salgado, S.W.B. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A randomized, double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis., 2021, 72(9), e373-e381.
[http://dx.doi.org/10.1093/cid/ciaa1177] [PMID: 32785710]

Favalli, E.G.; Ingegnoli, F.; De Lucia, O.; Cincinelli, G.; Cimaz, R.; Caporali, R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun. Rev., 2020, 19(5), 102523.
[http://dx.doi.org/10.1016/j.autrev.2020.102523] [PMID: 32205186]

Ma, J.; Muheem, A.; Rizvi, M. Coronavirus (COVID-19): History, current knowledge and pipeline medications. Int. J. Pharm., 2020, 4(1), 1-9.
[http://dx.doi.org/10.31531/2581-3080.1000140]

Pei, J.; Sekellick, M.J.; Marcus, P.I.; Choi, I.S.; Collisson, E.W. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. J. Interferon Cytokine Res., 2001, 21(12), 1071-1077.
[http://dx.doi.org/10.1089/107999001317205204] [PMID: 11798465]

Chen, F.; Chan, K.H.; Jiang, Y.; Kao, R.Y.T.; Lu, H.T.; Fan, K.W.; Cheng, V.C.C.; Tsui, W.H.W.; Hung, I.F.N.; Lee, T.S.W.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol., 2004, 31(1), 69-75.
[http://dx.doi.org/10.1016/j.jcv.2004.03.003] [PMID: 15288617]

Kuri, T.; Zhang, X.; Habjan, M.; Martínez-Sobrido, L.; García-Sastre, A.; Yuan, Z.; Weber, F. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. J. Gen. Virol., 2009, 90(11), 2686-2694.
[http://dx.doi.org/10.1099/vir.0.013599-0] [PMID: 19625461]

Tan, E.L.C.; Ooi, E.E.; Lin, C.Y.; Tan, H.C.; Ling, A.E.; Lim, B.; Stanton, L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis., 2004, 10(4), 581-586.
[http://dx.doi.org/10.3201/eid1004.030458] [PMID: 15200845]

Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.H.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 2001, 358(9286), 958-965.
[http://dx.doi.org/10.1016/S0140-6736(01)06102-5] [PMID: 11583749]

Deng, X.; Yu, X.; Pei, J. Regulation of interferon production as a potential strategy for COVID-19 treatment. arXiv, 2020, 2003.00751.

Omrani, A.S.; Saad, M.M.; Baig, K.; Bahloul, A.; Abdul-Matin, M.; Alaidaroos, A.Y.; Almakhlafi, G.A.; Albarrak, M.M.; Memish, Z.A.; Albarrak, A.M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect. Dis., 2014, 14(11), 1090-1095.
[http://dx.doi.org/10.1016/S1473-3099(14)70920-X] [PMID: 25278221]

Kalil, A.C. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA, 2020, 323(19), 1897-1898.
[http://dx.doi.org/10.1001/jama.2020.4742] [PMID: 32208486]

Gautret, P.; Lagier, J.C.; Honoré, S.; Hoang, V.T.; Colson, P.; Raoult, D.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Dupont, H.T. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open label non-randomized clinical trial revisited. Int. J. Antimicrob. Agents, 2021, 57(1), 106243.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106243] [PMID: 33408014]

Gautret, P.; Lagier, J.C.; Parola, P.; Hoang, V.T.; Meddeb, L.; Sevestre, J.; Mailhe, M.; Doudier, B.; Aubry, C.; Amrane, S.; Seng, P.; Hocquart, M.; Eldin, C.; Finance, J.; Vieira, V.E.; Tissot-Dupont, H.T.; Honoré, S.; Stein, A.; Million, M.; Colson, P.; La Scola, B.; Veit, V.; Jacquier, A.; Deharo, J.C.; Drancourt, M.; Fournier, P.E.; Rolain, J.M.; Brouqui, P.; Raoult, D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med. Infect. Dis., 2020, 34, 101663.
[http://dx.doi.org/10.1016/j.tmaid.2020.101663] [PMID: 32289548]

Javelot, H.; El-Hage, W.; Meyer, G.; Becker, G.; Michel, B.; Hingray, C. COVID-19 and (hydroxy)chloroquine–azithromycin combination: Should we take the risk for our patients? Br. J. Clin. Pharmacol., 2020, 86(6), 1176-1177.
[http://dx.doi.org/10.1111/bcp.14335] [PMID: 32350872]

Gbinigie, K.; Frie, K. Should azithromycin be used to treat COVID-19? A rapid review. BMJ open, 2020, 4(2), bjgpopen20X101094.
[http://dx.doi.org/10.3399/bjgpopen20X101094]

Andreani, J.; Le Bideau, M.; Duflot, I.; Jardot, P.; Rolland, C.; Boxberger, M.; Wurtz, N.; Rolain, J.M.; Colson, P.; La Scola, B.; Raoult, D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog., 2020, 145, 104228.
[http://dx.doi.org/10.1016/j.micpath.2020.104228] [PMID: 32344177]

Arikata, M.; Itoh, Y.; Shichinohe, S.; Nakayama, M.; Ishigaki, H.; Kinoshita, T.; Le, M.Q.; Kawaoka, Y.; Ogasawara, K.; Shimizu, T. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res., 2019, 171, 104591.
[http://dx.doi.org/10.1016/j.antiviral.2019.104591] [PMID: 31421167]

Takahashi, E.; Indalao, I.L.; Sawabuchi, T.; Mizuno, K.; Sakai, S.; Kimoto, T.; Kim, H.; Kido, H. Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. Comp. Immunol. Microbiol. Infect. Dis., 2018, 56, 6-13.
[http://dx.doi.org/10.1016/j.cimid.2017.11.002] [PMID: 29406285]

Amsden, G. Erythromycin, clarithromycin, and azithromycin: Are the differences real? Clin. Ther., 1996, 18(1), 56-72.
[http://dx.doi.org/10.1016/S0149-2918(96)80179-2] [PMID: 8851453]

Millán-Oñate, J.; Millan, W.; Mendoza, L.A.; Sánchez, C.G.; Fernandez-Suarez, H.; Bonilla-Aldana, D.K.; Rodríguez-Morales, A.J. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Ann. Clin. Microbiol. Antimicrob., 2020, 19(1), 16.
[http://dx.doi.org/10.1186/s12941-020-00358-y] [PMID: 32331519]

Zhou, N.; Pan, T.; Zhang, J.; Li, Q.; Zhang, X.; Bai, C.; Huang, F.; Peng, T.; Zhang, J.; Liu, C.; Tao, L.; Zhang, H. Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem., 2016, 291(17), 9218-9232.
[http://dx.doi.org/10.1074/jbc.M116.716100] [PMID: 26953343]

Wang, Y.; Cui, R.; Li, G.; Gao, Q.; Yuan, S.; Altmeyer, R.; Zou, G. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res., 2016, 125, 1-7.
[http://dx.doi.org/10.1016/j.antiviral.2015.11.003] [PMID: 26585243]

Baron, S.A.; Devaux, C.; Colson, P.; Raoult, D.; Rolain, J.M. Teicoplanin: An alternative drug for the treatment of COVID-19? Int. J. Antimicrob. Agents, 2020, 55(4), 105944.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105944] [PMID: 32179150]

Ceccarelli, G.; Alessandri, F.; d’Ettorre, G.; Borrazzo, C.; Spagnolello, O.; Oliva, A.; Ruberto, F.; Mastroianni, C.M.; Pugliese, F.; Venditti, M. Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int. J. Antimicrob. Agents, 2020, 56(2), 106029.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106029] [PMID: 32454071]

Fredeking, T.; Zavala-Castro, J.; González-Martínez, P.; Moguel-Rodríguez, W.; Sanchez, E.; Foster, M.; Diaz-Quijano, F. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Patents Anti-Infect. Drug Disc., 2015, 10(1), 51-58.
[http://dx.doi.org/10.2174/1574891X10666150410153839] [PMID: 25858261]

Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet, 2020, 395(10229), 1033-1034.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]

Quartuccio, L.; Semerano, L.; Benucci, M.; Boissier, M.C.; De Vita, S. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine, 2020, 87(3), 191-193.
[http://dx.doi.org/10.1016/j.jbspin.2020.03.011] [PMID: 32321634]

Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; Zheng, M.; Chen, L.; Li, H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B, 2020, 10(5), 766-788.
[http://dx.doi.org/10.1016/j.apsb.2020.02.008] [PMID: 32292689]

De Clercq, E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev. Anti Infect. Ther., 2006, 4(2), 291-302.
[http://dx.doi.org/10.1586/14787210.4.2.291] [PMID: 16597209]

Wang, J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J. Chem. Inf. Model., 2020, 60(6), 3277-3286.
[http://dx.doi.org/10.1021/acs.jcim.0c00179] [PMID: 32315171]

Thiem, U.; Heppner, H.J.; Pientka, L. Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging, 2011, 28(7), 519-537.
[http://dx.doi.org/10.2165/11591980-000000000-00000] [PMID: 21721597]

Durojaiye, A.B.; Clarke, J.R.D.; Stamatiades, G.A.; Wang, C. Repurposing cefuroxime for treatment of COVID-19: A scoping review of in silico studies. J. Biomol. Struct. Dyn., 2021, 39(12), 4547-4554.
[http://dx.doi.org/10.1080/07391102.2020.1777904] [PMID: 32538276]

Almutairi, A.S.; Abunurah, H.; Hadi Alanazi, A.; Alenezi, F.K.; Nagy, H.; Saad Almutairi, N.; Wells, M.; Alawam, A.; Alqahtani, M.M. The immunological response among COVID-19 patients with acute respiratory distress syndrome. J. Infect. Public Health, 2021, 14(7), 954-959.
[http://dx.doi.org/10.1016/j.jiph.2021.05.007] [PMID: 34130119]

van Paassen, J.; Vos, J.S.; Hoekstra, E.M.; Neumann, K.M.I.; Boot, P.C.; Arbous, S.M. Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit. Care, 2020, 24(1), 696.
[http://dx.doi.org/10.1186/s13054-020-03400-9] [PMID: 33317589]

Cheng, B.; Ma, J.; Yang, Y.; Shao, T.; Zhao, B.; Zeng, L. Systemic corticosteroid administration in coronavirus disease 2019 outcomes: An umbrella meta-analysis incorporating both mild and pulmonary fibrosis–manifested severe disease. Front. Pharmacol., 2021, 12, 670170.
[http://dx.doi.org/10.3389/fphar.2021.670170] [PMID: 34122093]

Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Chappell, L.C.; Faust, S.N.; Jaki, T.; Jeffery, K.; Montgomery, A.; Rowan, K.; Juszczak, E.; Baillie, J.K.; Haynes, R.; Landray, M.J. Dexamethasone in hospitalized patients with covid-19. N. Engl. J. Med., 2021, 384(8), 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]

Kluge, S.; Janssens, U.; Welte, T.; Weber-Carstens, S.; Schälte, G.; Spinner, C.D.; Malin, J.J.; Gastmeier, P.; Langer, F.; Wepler, M.; Westhoff, M.; Pfeifer, M.; Rabe, K.F.; Hoffmann, F.; Böttiger, B.W.; Weinmann-Menke, J.; Kersten, A.; Berlit, P.; Haase, R.; Marx, G.; Karagiannidis, C. S2k-Leitlinie – empfehlungen zur stationären therapie von patienten mit COVID-19. Pneumologie, 2021, 75(2), 88-112.
[http://dx.doi.org/10.1055/a-1334-1925] [PMID: 33450783]

Daminova, N. The European medicines agency ‘transparency’ policies, the CJEU and COVID-19: Do the CFREU provisions retain any relevance? MTA LAW WORKING PAPERS, 2021, 1(8), 1-32.

Bartoletti, M.; Azap, O.; Barac, A.; Bussini, L.; Ergonul, O.; Krause, R.; Paño-Pardo, J.R.; Power, N.R.; Sibani, M.; Szabo, B.G.; Tsiodras, S.; Verweij, P.E.; Zollner-Schwetz, I.; Rodríguez-Baño, J. ESCMID COVID-19 living guidelines: Drug treatment and clinical management. Clin Microbiol Infect, 2022, 28(2), 222-238.
[http://dx.doi.org/10.1016/j.cmi.2021.11.007]

Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; Song, J.; Wang, S.; Chao, Y.; Yang, Z.; Xu, J.; Zhou, X.; Chen, D.; Xiong, W.; Xu, L.; Zhou, F.; Jiang, J.; Bai, C.; Zheng, J.; Song, Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, 180(7), 934-943.
[http://dx.doi.org/10.1001/jamainternmed.2020.0994] [PMID: 32167524]

Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223), 473-475.
[http://dx.doi.org/10.1016/S0140-6736(20)30317-2] [PMID: 32043983]

Bahl, A.; Johnson, S.; Chen, N.W. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern. Emerg. Med., 2021, 16(6), 1593-1603.
[http://dx.doi.org/10.1007/s11739-021-02655-6] [PMID: 33547620]

Bretagne, S.; Sitbon, K.; Botterel, F.; Dellière, S.; Letscher-Bru, V.; Chouaki, T.; Bellanger, A.P.; Bonnal, C.; Fekkar, A.; Persat, F.; Costa, D.; Bourgeois, N.; Dalle, F.; Lussac-Sorton, F.; Paugam, A.; Cassaing, S.; Hasseine, L.; Huguenin, A.; Guennouni, N.; Mazars, E.; Le Gal, S.; Sasso, M.; Brun, S.; Cadot, L.; Cassagne, C.; Cateau, E.; Gangneux, J.P.; Moniot, M.; Roux, A.L.; Tournus, C.; Desbois-Nogard, N.; Le Coustumier, A.; Moquet, O.; Alanio, A.; Dromer, F. COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: A retrospective multicenter observational cohort during the first French pandemic wave. Microbiol. Spectr., 2021, 9(2), e01138-21.
[http://dx.doi.org/10.1128/Spectrum.01138-21] [PMID: 34668768]

Li, H.; Chen, C.; Hu, F.; Wang, J.; Zhao, Q.; Gale, R.P.; Liang, Y. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: A systematic review and meta-analysis. Leukemia, 2020, 34(6), 1503-1511.
[http://dx.doi.org/10.1038/s41375-020-0848-3] [PMID: 32372026]

Budhathoki, P.; Shrestha, D.B.; Rawal, E.; Khadka, S. Corticosteroids in COVID-19: Is it rational? A systematic review and meta-analysis. SN Compr. Clin. Med., 2020, 2(12), 2600-2620.
[http://dx.doi.org/10.1007/s42399-020-00515-6] [PMID: 33103063]

Day, M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ, 2020, 368, m1168.
[http://dx.doi.org/10.1136/bmj.m1168] [PMID: 32205306]

Little, P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ, 2020, 368, m1185.
[http://dx.doi.org/10.1136/bmj.m1185] [PMID: 32220865]

McManus, N.; Offman, R.; Oetman, J. Emergency department management of COVID-19: An evidence-based approach. West. J. Emerg. Med., 2020, 21(6), 32-44.
[http://dx.doi.org/10.5811/westjem.2020.8.48288] [PMID: 33052814]

Amici, C.; Caro, A.D.; Ciucci, A.; Chiappa, L.; Castilletti, C.; Martella, V.; Decaro, N.; Buonavoglia, C.; Capobianchi, M.R.; Santoro, M.G. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir. Ther., 2006, 11(8), 1021-1030.
[http://dx.doi.org/10.1177/135965350601100803] [PMID: 17302372]

Patel, A.B.; Verma, A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA, 2020, 323(18), 1769-1770.
[http://dx.doi.org/10.1001/jama.2020.4812] [PMID: 32208485]

Sommerstein, R.; Kochen, M.M.; Messerli, F.H.; Gräni, C. Coronavirus disease 2019 (COVID-19): Do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J. Am. Heart Assoc., 2020, 9(7), e016509.
[http://dx.doi.org/10.1161/JAHA.120.016509] [PMID: 32233753]

Warner, F.J.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Angiotensin-converting enzyme-2: A molecular and cellular perspective. Cell. Mol. Life Sci., 2004, 61(21), 2704-2713.
[http://dx.doi.org/10.1007/s00018-004-4240-7] [PMID: 15549171]

Dimitrov, D.S. The secret life of ACE2 as a receptor for the SARS virus. Cell, 2003, 115(6), 652-653.
[http://dx.doi.org/10.1016/S0092-8674(03)00976-0] [PMID: 14675530]

Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; Choe, H.; Farzan, M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426(6965), 450-454.
[http://dx.doi.org/10.1038/nature02145] [PMID: 14647384]

Simmons, G.; Reeves, J.D.; Rennekamp, A.J.; Amberg, S.M.; Piefer, A.J.; Bates, P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci., 2004, 101(12), 4240-4245.
[http://dx.doi.org/10.1073/pnas.0306446101] [PMID: 15010527]

Yeung, K.S.; Yamanaka, G.A.; Meanwell, N.A. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Med. Res. Rev., 2006, 26(4), 414-433.
[http://dx.doi.org/10.1002/med.20055] [PMID: 16521129]

Diaz, J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J. Travel Med., 2020, 27(3), taaa041.
[http://dx.doi.org/10.1093/jtm/taaa041] [PMID: 32186711]

Rothan, H.A.; Byrareddy, S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun., 2020, 109, 102433.
[http://dx.doi.org/10.1016/j.jaut.2020.102433] [PMID: 32113704]

Hussain, A.; Bhowmik, B.; do Vale Moreira, N.C. COVID-19 and diabetes: Knowledge in progress. Diabetes Res. Clin. Pract., 2020, 162, 108142.
[http://dx.doi.org/10.1016/j.diabres.2020.108142] [PMID: 32278764]

Muniyappa, R.; Gubbi, S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am. J. Physiol. Endocrinol. Metab., 2020, 318(5), E736-E741.
[http://dx.doi.org/10.1152/ajpendo.00124.2020] [PMID: 32228322]

Allard, R.; Leclerc, P.; Tremblay, C.; Tannenbaum, T.N. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care, 2010, 33(7), 1491-1493.
[http://dx.doi.org/10.2337/dc09-2215] [PMID: 20587722]

Targher, G.; Mantovani, A.; Wang, X.B.; Yan, H.D.; Sun, Q.F.; Pan, K.H.; Byrne, C.D.; Zheng, K.I.; Chen, Y.P.; Eslam, M.; George, J.; Zheng, M.H. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab., 2020, 46(4), 335-337.
[http://dx.doi.org/10.1016/j.diabet.2020.05.001] [PMID: 32416321]

Fadini, G.P.; Morieri, M.L.; Longato, E.; Avogaro, A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J. Endocrinol. Invest., 2020, 43(6), 867-869.
[http://dx.doi.org/10.1007/s40618-020-01236-2] [PMID: 32222956]

Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; Zhao, L.; Fan, H.; Luo, S.; Hu, D. Diabetes is a risk factor for the progression and prognosis of COVID -19. Diabetes Metab. Res. Rev., 2020, 36(7), e3319.
[http://dx.doi.org/10.1002/dmrr.3319] [PMID: 32233013]

Stoian, A.P.; Banerjee, Y.; Rizvi, A.A.; Rizzo, M. Diabetes and the COVID-19 pandemic: How insights from recent experience might guide future management. Metab. Syndr. Relat. Disord., 2020, 18(4), 173-175.
[http://dx.doi.org/10.1089/met.2020.0037] [PMID: 32271125]

Bornstein, S.R.; Dalan, R.; Hopkins, D.; Mingrone, G.; Boehm, B.O. Endocrine and metabolic link to coronavirus infection. Nat. Rev. Endocrinol., 2020, 16(6), 297-298.
[http://dx.doi.org/10.1038/s41574-020-0353-9] [PMID: 32242089]

Sardu, C.; D’Onofrio, N.; Balestrieri, M.L.; Barbieri, M.; Rizzo, M.R.; Messina, V.; Maggi, P.; Coppola, N.; Paolisso, G.; Marfella, R. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care, 2020, 43(7), 1408-1415.
[http://dx.doi.org/10.2337/dc20-0723] [PMID: 32430456]

Solerte, S.B.; D’Addio, F.; Trevisan, R.; Lovati, E.; Rossi, A.; Pastore, I.; Dell’Acqua, M.; Ippolito, E.; Scaranna, C.; Bellante, R.; Galliani, S.; Dodesini, A.R.; Lepore, G.; Geni, F.; Fiorina, R.M.; Catena, E.; Corsico, A.; Colombo, R.; Mirani, M.; De Riva, C.; Oleandri, S.E.; Abdi, R.; Bonventre, J.V.; Rusconi, S.; Folli, F.; Di Sabatino, A.; Zuccotti, G.; Galli, M.; Fiorina, P. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: A multicenter, case-control, retrospective, observational study. Diabetes Care, 2020, 43(12), 2999-3006.
[http://dx.doi.org/10.2337/dc20-1521] [PMID: 32994187]

Sun, Q.; Li, J.; Gao, F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J. Diabetes, 2014, 5(2), 89-96.
[http://dx.doi.org/10.4239/wjd.v5.i2.89] [PMID: 24765237]

Salem, E.S.B.; Grobe, N.; Elased, K.M. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am. J. Physiol. Renal Physiol., 2014, 306(6), F629-F639.
[http://dx.doi.org/10.1152/ajprenal.00516.2013] [PMID: 24452639]

Chen, Y.; Yang, D.; Cheng, B.; Chen, J.; Peng, A.; Yang, C.; Liu, C.; Xiong, M.; Deng, A.; Zhang, Y.; Zheng, L.; Huang, K. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care, 2020, 43(7), 1399-1407.
[http://dx.doi.org/10.2337/dc20-0660] [PMID: 32409498]

Xian, H.; Liu, Y.; Nilsson, A.R.; Gatchalian, R.; Crother, T.R.; Tourtellotte, W.G.; Zhang, Y.; Aleman-Muench, G.R.; Lewis, G.; Chen, W. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity, 2021, 54(7), 1463-1477. e1411..
[http://dx.doi.org/10.1016/j.immuni.2021.05.004]

Bramante, C.T.; Ingraham, N.E.; Murray, T.A.; Marmor, S.; Hovertsen, S.; Gronski, J.; McNeil, C.; Feng, R.; Guzman, G.; Abdelwahab, N.; King, S.; Tamariz, L.; Meehan, T.; Pendleton, K.M.; Benson, B.; Vojta, D.; Tignanelli, C.J. Metformin and risk of mortality in patients hospitalised with COVID-19: A retrospective cohort analysis. Lancet Healthy Longev., 2021, 2(1), e34-e41.
[http://dx.doi.org/10.1016/S2666-7568(20)30033-7] [PMID: 33521772]

Lalau, J.D.; Al-Salameh, A.; Hadjadj, S.; Goronflot, T.; Wiernsperger, N.; Pichelin, M.; Allix, I.; Amadou, C.; Bourron, O.; Duriez, T.; Gautier, J.F.; Dutour, A.; Gonfroy, C.; Gouet, D.; Joubert, M.; Julier, I.; Larger, E.; Marchand, L.; Marre, M.; Meyer, L.; Olivier, F.; Prevost, G.; Quiniou, P.; Raffaitin-Cardin, C.; Roussel, R.; Saulnier, P.J.; Seret-Begue, D.; Thivolet, C.; Vatier, C.; Desailloud, R.; Wargny, M.; Gourdy, P.; Cariou, B. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab., 2021, 47(5), 101216.
[http://dx.doi.org/10.1016/j.diabet.2020.101216] [PMID: 33309936]

Luo, P.; Qiu, L.; Liu, Y.; Liu, X.; Zheng, J.; Xue, H.; Liu, W.; Liu, D.; Li, J. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am. J. Trop. Med. Hyg., 2020, 103(1), 69-72.
[http://dx.doi.org/10.4269/ajtmh.20-0375] [PMID: 32446312]

Apostolova, N.; Iannantuoni, F.; Gruevska, A.; Muntane, J.; Rocha, M.; Victor, V.M. Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. Redox Biol., 2020, 34, 101517.
[http://dx.doi.org/10.1016/j.redox.2020.101517] [PMID: 32535544]

Cheng, X.; Liu, Y.-M.; Li, H.; Zhang, X.; Lei, F.; Qin, J.-J.; Chen, Z.; Deng, K.-Q.; Lin, L.; Chen, M.-M. Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes. Cell metabolism, 2020, 32(4), 537-547. e533..
[http://dx.doi.org/10.1016/j.cmet.2020.08.013]

Gao, Y.; Liu, T.; Zhong, W.; Liu, R.; Zhou, H.; Huang, W.; Zhang, W. Risk of metformin in patients with type 2 diabetes with COVID-19: A preliminary retrospective report. Clin. Transl. Sci., 2020, 13(6), 1055-1059.
[http://dx.doi.org/10.1111/cts.12897] [PMID: 32955785]

Apicella, M.; Campopiano, M.C.; Mantuano, M.; Mazoni, L.; Coppelli, A.; Del Prato, S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol., 2020, 8(9), 782-792.
[http://dx.doi.org/10.1016/S2213-8587(20)30238-2] [PMID: 32687793]

Katsiki, N.; Banach, M.; Mikhailidis, D. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch. Med. Sci., 2020, 16(3), 485-489.
[http://dx.doi.org/10.5114/aoms.2020.94503] [PMID: 32399093]

Pratelli, A.; Colao, V. Role of the lipid rafts in the life cycle of canine coronavirus. J. Gen. Virol., 2015, 96(2), 331-337.
[http://dx.doi.org/10.1099/vir.0.070870-0] [PMID: 25381058]

Schönbeck, U.; Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation, 2004, 109(S21), II18-II26.
[http://dx.doi.org/10.1161/01.CIR.0000129505.34151.23] [PMID: 15173059]

Baden, L.R.; Rubin, E.J. Covid-19 — the search for effective therapy. N. Engl. J. Med., 2020, 382(19), 1851-1852.
[http://dx.doi.org/10.1056/NEJMe2005477] [PMID: 32187463]

Tay, M.Y.F.; Fraser, J.E.; Chan, W.K.K.; Moreland, N.J.; Rathore, A.P.; Wang, C.; Vasudevan, S.G.; Jans, D.A. Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res., 2013, 99(3), 301-306.
[http://dx.doi.org/10.1016/j.antiviral.2013.06.002] [PMID: 23769930]

Tu, Y.F.; Chien, C.S.; Yarmishyn, A.A.; Lin, Y.Y.; Luo, Y.H.; Lin, Y.T.; Lai, W.Y.; Yang, D.M.; Chou, S.J.; Yang, Y.P.; Wang, M.L.; Chiou, S.H. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci., 2020, 21(7), 2657.
[http://dx.doi.org/10.3390/ijms21072657] [PMID: 32290293]

Yang, S.N.Y.; Atkinson, S.C.; Wang, C.; Lee, A.; Bogoyevitch, M.A.; Borg, N.A.; Jans, D.A. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res., 2020, 177, 104760.
[http://dx.doi.org/10.1016/j.antiviral.2020.104760] [PMID: 32135219]

Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 2020, 178, 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]

Lundberg, L.; Pinkham, C.; Baer, A.; Amaya, M.; Narayanan, A.; Wagstaff, K.M.; Jans, D.A.; Kehn-Hall, K. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res., 2013, 100(3), 662-672.
[http://dx.doi.org/10.1016/j.antiviral.2013.10.004] [PMID: 24161512]

Guzzo, C.A.; Furtek, C.I.; Porras, A.G.; Chen, C.; Tipping, R.; Clineschmidt, C.M.; Sciberras, D.G.; Hsieh, J.Y.K.; Lasseter, K.C. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol., 2002, 42(10), 1122-1133.
[http://dx.doi.org/10.1177/009127002237994] [PMID: 12362927]

Muñoz, J.; Ballester, M.R.; Antonijoan, R.M.; Gich, I.; Rodríguez, M.; Colli, E.; Gold, S.; Krolewiecki, A.J. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl. Trop. Dis., 2018, 12(1), e0006020.
[http://dx.doi.org/10.1371/journal.pntd.0006020] [PMID: 29346388]

Bryant, A.; Lawrie, T.A.; Dowswell, T.; Fordham, E.J.; Mitchell, S.; Hill, S.R.; Tham, T.C. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am. J. Ther., 2021, 28(4), e434-e460.
[http://dx.doi.org/10.1097/MJT.0000000000001402] [PMID: 34145166]

Kaur, H.; Shekhar, N.; Sharma, S.; Sarma, P.; Prakash, A.; Medhi, B. Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol. Rep., 2021, 73(3), 736-749.
[http://dx.doi.org/10.1007/s43440-020-00195-y] [PMID: 33389725]

Altay, O.; Mohammadi, E.; Lam, S.; Turkez, H.; Boren, J.; Nielsen, J.; Uhlen, M.; Mardinoglu, A. Current status of COVID-19 therapies and drug repositioning applications. iScience, 2020, 23(7), 101303.
[http://dx.doi.org/10.1016/j.isci.2020.101303] [PMID: 32622261]

Gao, K.; Nguyen, D.D.; Chen, J.; Wang, R.; Wei, G.W. Repositioning of 8565 existing drugs for COVID-19. J. Phys. Chem. Lett., 2020, 11(13), 5373-5382.
[http://dx.doi.org/10.1021/acs.jpclett.0c01579] [PMID: 32543196]

Pindiprolu, S.K.S.S.; Pindiprolu, S.H. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Med. Hypotheses, 2020, 140, 109765.
[http://dx.doi.org/10.1016/j.mehy.2020.109765] [PMID: 32361588]

Gassen, N.C.; Papies, J.; Bajaj, T.; Emanuel, J.; Dethloff, F.; Chua, R.L.; Trimpert, J.; Heinemann, N.; Niemeyer, C.; Weege, F.; Hönzke, K.; Aschman, T.; Heinz, D.E.; Weckmann, K.; Ebert, T.; Zellner, A.; Lennarz, M.; Wyler, E.; Schroeder, S.; Richter, A.; Niemeyer, D.; Hoffmann, K.; Meyer, T.F.; Heppner, F.L.; Corman, V.M.; Landthaler, M.; Hocke, A.C.; Morkel, M.; Osterrieder, N.; Conrad, C.; Eils, R.; Radbruch, H.; Giavalisco, P.; Drosten, C.; Müller, M.A. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat. Commun., 2021, 12(1), 3818.
[http://dx.doi.org/10.1038/s41467-021-24007-w] [PMID: 34155207]

Stachulski, A.V.; Taujanskas, J.; Pate, S.L.; Rajoli, R.K.R.; Aljayyoussi, G.; Pennington, S.H.; Ward, S.A.; Hong, W.D.; Biagini, G.A.; Owen, A.; Nixon, G.L.; Leung, S.C.; O’Neill, P.M. Therapeutic potential of nitazoxanide: An appropriate choice for repurposing versus SARS-CoV-2? ACS Infect. Dis., 2021, 7(6), 1317-1331.
[http://dx.doi.org/10.1021/acsinfecdis.0c00478] [PMID: 33352056]

Bobrowski, T.; Chen, L.; Eastman, R.T.; Itkin, Z.; Shinn, P.; Chen, C.Z.; Guo, H.; Zheng, W.; Michael, S.; Simeonov, A.; Hall, M.D.; Zakharov, A.V.; Muratov, E.N. Synergistic and antagonistic drug combinations against SARS-CoV-2. Mol. Ther., 2021, 29(2), 873-885.
[http://dx.doi.org/10.1016/j.ymthe.2020.12.016] [PMID: 33333292]

Pascoalino, B.S.; Courtemanche, G.; Cordeiro, M.T.; Gil, L.H.V.G.; Freitas-Junior, L.H. Zika antiviral chemotherapy: Identification of drugs and promising starting points for drug discovery from an FDA-approved library. F1000 Res., 2016, 5, 2523.
[http://dx.doi.org/10.12688/f1000research.9648.1] [PMID: 27909576]

Tonelli, M.; Simone, M.; Tasso, B.; Novelli, F.; Boido, V.; Sparatore, F.; Paglietti, G.; Pricl, S.; Giliberti, G.; Blois, S.; Ibba, C.; Sanna, G.; Loddo, R.; La Colla, P. Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. Bioorg. Med. Chem., 2010, 18(8), 2937-2953.
[http://dx.doi.org/10.1016/j.bmc.2010.02.037] [PMID: 20359898]

Law, J.N.; Akers, K.; Tasnina, N.; Santina, C.M.D.; Deutsch, S.; Kshirsagar, M.; Klein-Seetharaman, J.; Crovella, M.; Rajagopalan, P.; Kasif, S.; Murali, T.M. Interpretable network propagation with application to expanding the repertoire of human proteins that interact with SARS-CoV-2. Gigascience, 2021, 10(12), giab082.
[http://dx.doi.org/10.1093/gigascience/giab082] [PMID: 34966926]

Rainsford, K.D. Influenza (“Bird Flu”), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology, 2006, 14(1-2), 2-9.
[http://dx.doi.org/10.1007/s10787-006-0002-5] [PMID: 16835706]

Srinivasan, V.; Mohamed, M.; Kato, H. Melatonin in bacterial and viral infections with focus on sepsis: A review. Recent Pat. Endocr. Metab. Immune Drug Discov., 2012, 6(1), 30-39.
[http://dx.doi.org/10.2174/187221412799015317] [PMID: 22264213]

Tan, D.X.; Korkmaz, A.; Reiter, R.J.; Manchester, L.C. Ebola virus disease: Potential use of melatonin as a treatment. J. Pineal Res., 2014, 57(4), 381-384.
[http://dx.doi.org/10.1111/jpi.12186] [PMID: 25262626]

Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res., 2007, 42(1), 28-42.
[http://dx.doi.org/10.1111/j.1600-079X.2006.00407.x] [PMID: 17198536]

Galano, A.; Tan, D.X.; Reiter, R.J. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J. Pineal Res., 2013, 54(3), 245-257.
[http://dx.doi.org/10.1111/jpi.12010] [PMID: 22998574]

Xiao, J.; Shimada, M.; Liu, W.; Hu, D.; Matsumori, A. Anti-inflammatory effects of eplerenone on viral myocarditis. Eur. J. Heart Fail., 2009, 11(4), 349-353.
[http://dx.doi.org/10.1093/eurjhf/hfp023] [PMID: 19213804]

Zhao, Y.; Ren, J.; Harlos, K.; Jones, D.M.; Zeltina, A.; Bowden, T.A.; Padilla-Parra, S.; Fry, E.E.; Stuart, D.I. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature, 2016, 535(7610), 169-172.
[http://dx.doi.org/10.1038/nature18615] [PMID: 27362232]

Schwarz, S.; Wang, K.; Yu, W.; Sun, B.; Schwarz, W. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res., 2011, 90(1), 64-69.
[http://dx.doi.org/10.1016/j.antiviral.2011.02.008] [PMID: 21356245]

Ho, T.; Wu, S.; Chen, J.; Li, C.; Hsiang, C. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res., 2007, 74(2), 92-101.
[http://dx.doi.org/10.1016/j.antiviral.2006.04.014] [PMID: 16730806]